Bioworld Insider

New therapies vie to change fatal course of amyotrophic lateral sclerosis

As multidisciplinary care extends survival and improves the quality of life for people with amyotrophic lateral sclerosis (ALS), can a host of new ALS drugs vying to slow its progression make a difference? A surprise extension of the U.S. FDA review for Amylyx Therapeutics Inc.’s AMX-0035 to review new data, plus near-term readouts from a major ALS platform trial may soon provide answers. Join the BioWorld Insider podcast as we talk with executives from Amylyx and Clene Inc., and a key Penn State ALS expert on what the future of medicine may hold for ALS patients.

Zachary Simmons
Professor and vice chair for research
Penn State Department of Neurology
Rob Etherington
President and CEO
Clene Nanomedicine
Justin Klee
Co-CEO and co-founder
Amylyx Pharmaceuticals
Josh Cohen
Co-CEO and co-founder
Amylyx Pharmaceuticals